3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial
CW Le Roux, A Astrup, K Fujioka, F Greenway… - The Lancet, 2017 - thelancet.com
Background Liraglutide 3· 0 mg was shown to reduce bodyweight and improve glucose
metabolism after the 56-week period of this trial, one of four trials in the SCALE programme.
In the 3-year assessment of the SCALE Obesity and Prediabetes trial we aimed to evaluate
the proportion of individuals with prediabetes who were diagnosed with type 2 diabetes.
Methods In this randomised, double-blind, placebo-controlled trial, adults with prediabetes
and a body-mass index of at least 30 kg/m 2, or at least 27 kg/m 2 with comorbidities, were …
metabolism after the 56-week period of this trial, one of four trials in the SCALE programme.
In the 3-year assessment of the SCALE Obesity and Prediabetes trial we aimed to evaluate
the proportion of individuals with prediabetes who were diagnosed with type 2 diabetes.
Methods In this randomised, double-blind, placebo-controlled trial, adults with prediabetes
and a body-mass index of at least 30 kg/m 2, or at least 27 kg/m 2 with comorbidities, were …
3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial
SCALE Obesity Prediabetes NN8022-1839 Study … - The Lancet, 2017 - cris.bgu.ac.il
Background Liraglutide 3· 0 mg was shown to reduce bodyweight and improve glucose
metabolism after the 56-week period of this trial, one of four trials in the SCALE programme.
In the 3-year assessment of the SCALE Obesity and Prediabetes trial we aimed to evaluate
the proportion of individuals with prediabetes who were diagnosed with type 2 diabetes.
Methods In this randomised, double-blind, placebo-controlled trial, adults with prediabetes
and a body-mass index of at least 30 kg/m 2, or at least 27 kg/m 2 with comorbidities, were …
metabolism after the 56-week period of this trial, one of four trials in the SCALE programme.
In the 3-year assessment of the SCALE Obesity and Prediabetes trial we aimed to evaluate
the proportion of individuals with prediabetes who were diagnosed with type 2 diabetes.
Methods In this randomised, double-blind, placebo-controlled trial, adults with prediabetes
and a body-mass index of at least 30 kg/m 2, or at least 27 kg/m 2 with comorbidities, were …
以上显示的是最相近的搜索结果。 查看全部搜索结果